Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Chronological Source Flow
Back

AI Fusion Summary

Protara Therapeutics (TARA) has a consensus moderate buy rating from seven analysts, with one sell, five buy, and one strong buy. The average 12‑month target is $21.40, and recent notes from TD Cowen and JPMorgan reaffirm the positive outlook.
#Protara Therapeutics #TARA #consensus rating #moderate buy #price target #TD Cowen #JPMorgan #equities research
01/04 09:56 defenseworld.net
3 Πηγές

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Protara TherapeuticsTARAconsensus ratingmoderate buyprice targetTD Cowen
01/04 11:42 defenseworld.net

KANZHUN LIMITED Sponsored ADR (NASDAQ:BZ) Given Average Recommendation of “Moderate Buy” by Brokerages

CONSENSUS RATING ARTICLESCOMPANIESPOLITICS
01/04 11:43 defenseworld.net

Everus Construction Group, Inc. (NYSE:ECG) Given Consensus Rating of “Moderate Buy” by Brokerages

CONSENSUS RATING ARTICLESCOMPANIESPOLITICS
Comments
Loading...
0